MorphoSys AG — Investor Presentation 2007

Nov 5, 2007

GPC Biotech: 1D09C3	Hoffmann-La Roche: R1450
" HuCAL antibody vs. MHCII (HLA-DR)	" HuCAL antibody vs. amyloid-β for
for relapsed and refractory lymphoma	Alzheimer's Disease
" European phase 1 study at 3 sites,	" Europ. phase 1 study ongoing at 4 sites:
patient recruitment completed	randomized, double-blinded, in patients
" Antibody seems safe and well-tolerated	" Results expected 2008 (MOR estimate)
Undisclosed Partner	Novartis
" HuCAL antibody vs. undisclosed cancer	" HuCAL antibody vs. undisclosed cancer
target	target
" IND filing in June 2007	" 3 years from start of project to IND

MOR 103
MOR202
" Primary Indication: Multiple myeloma
" Medical Need:
ƒ Few available treatment options for MM, no curative therapies
" Drug Candidate:
ƒ HuCAL antibodies vs. CD 38, a 45kDa glycoprotein
ƒ Compelling efficacy data in vitro and in vivo (SCID mouse)
" Milestones:
ƒ 2007: Profiling of lead and one back-up candidate

Financial Growth
In EUR millions	Guidance 2007	2006	2005
Revenues
Segment Therapeutic Antibodies	2/3 of total revenues	34.7	29.1
Segment AbD	1/3 of total revenues	18.3	4.3
Total Revenues	60 - 65	53.0	33.5*
Total Operating Expenses	-	46.9	27.3
Profit from Operations	7 - 10	6.2*	6.2
				* Differences due to rounding
MorphoSys AG Company Presentation November 2007				© MorphoSys AG Page 17

In EUR millions	9-Months 2007	9-Months 2006
Revenues	44.1	39.0
Cost of Goods Sold	6.0	5.5
R&D Expenses	15.7	11.7
S,G&A Expenses	15.5	14.0
Total Operating Expenses	37.2	31.2
Profit from Operations	6.9	7.8
Non-Operating Income/(Expenses)	0.9	(0.3)
Profit Before Taxes	7.8	7.4*
Income Tax Expense	2.9	1.2
Net Profit	4.9	6.1*
Earnings per Share (diluted) in EUR	0.68	0.93

Condensed Balance Sheets (Group) 9-Months 2007

Assets
Cash, Cash Equivalents & Marketable Securities	105.0	66.0
Other Current Assets	15.5	10.1
Total Non-Current Assets	48.1	51.7
Total Assets	168.6	127.8
Liabilities
Total Current Liabilities	18.4	18.3
Total Non-Current Liabilities	11.3	9.5
Total Shareholders' Equity	138.8	100.1
Total Liabilities	168.6*	127.8*